Haematological Malignancies, Lymphoma
Novel Therapy of Relapsed and Refractory Classical Hodgkin’s Lymphoma
Enrico Derenzini, Daniela Buglio, Anas Younes
Although Hodgkin’s lymphoma (HL) is considered one of the most curable human cancers, the treatment of patients with relapsed and refractory disease, especially those who relapse after autologous stem cell transplantation (ASCT), remains challenging.1,2 Furthermore, because the median age of patients is in the mid-30s, the impact of early mortality on the number of years […]